Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 10.62
APPY's Cash to Debt is ranked higher than
73% of the 294 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. APPY: 10.62 )
APPY' s 10-Year Cash to Debt Range
Min: 0.03   Max: 10.62
Current: 10.62

0.03
10.62
Equity to Asset 0.83
APPY's Equity to Asset is ranked higher than
91% of the 279 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. APPY: 0.83 )
APPY' s 10-Year Equity to Asset Range
Min: -0.03   Max: 0.84
Current: 0.83

-0.03
0.84
F-Score: 5
Z-Score: -3.11
M-Score: -1.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3970.99
APPY's Operating margin (%) is ranked lower than
56% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. APPY: -3970.99 )
APPY' s 10-Year Operating margin (%) Range
Min: -14454.84   Max: 17.54
Current: -3970.99

-14454.84
17.54
Net-margin (%) -3986.26
APPY's Net-margin (%) is ranked lower than
55% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. APPY: -3986.26 )
APPY' s 10-Year Net-margin (%) Range
Min: -14858.06   Max: 8.99
Current: -3986.26

-14858.06
8.99
ROE (%) -50.78
APPY's ROE (%) is ranked higher than
54% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. APPY: -50.78 )
APPY' s 10-Year ROE (%) Range
Min: -1390.28   Max: -40.1
Current: -50.78

-1390.28
-40.1
ROA (%) -40.56
APPY's ROA (%) is ranked higher than
55% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. APPY: -40.56 )
APPY' s 10-Year ROA (%) Range
Min: -78.91   Max: -30.69
Current: -40.56

-78.91
-30.69
ROC (Joel Greenblatt) (%) -477.82
APPY's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 294 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. APPY: -477.82 )
APPY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -509.39   Max: -33.47
Current: -477.82

-509.39
-33.47
Revenue Growth (3Y)(%) -63.80
APPY's Revenue Growth (3Y)(%) is ranked higher than
51% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. APPY: -63.80 )
APPY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -68.8   Max: -2.3
Current: -63.8

-68.8
-2.3
EBITDA Growth (3Y)(%) -63.40
APPY's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. APPY: -63.40 )
APPY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.4   Max: 43.8
Current: -63.4

-63.4
43.8
EPS Growth (3Y)(%) -63.80
APPY's EPS Growth (3Y)(%) is ranked higher than
50% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. APPY: -63.80 )
APPY' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.8   Max: 37.8
Current: -63.8

-63.8
37.8
» APPY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with APPY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.60
APPY's P/B is ranked higher than
99% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. APPY: 0.60 )
APPY' s 10-Year P/B Range
Min: 0.52   Max: 38.96
Current: 0.6

0.52
38.96
P/S 53.40
APPY's P/S is ranked lower than
68% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.66 vs. APPY: 53.40 )
APPY' s 10-Year P/S Range
Min: 0   Max: 346.37
Current: 53.4

0
346.37
EV-to-EBIT 0.78
APPY's EV-to-EBIT is ranked higher than
100% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. APPY: 0.78 )
APPY' s 10-Year EV-to-EBIT Range
Min: -81.4   Max: 0.5
Current: 0.78

-81.4
0.5
Current Ratio 13.97
APPY's Current Ratio is ranked higher than
98% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. APPY: 13.97 )
APPY' s 10-Year Current Ratio Range
Min: 0.31   Max: 13.97
Current: 13.97

0.31
13.97
Quick Ratio 13.97
APPY's Quick Ratio is ranked higher than
98% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. APPY: 13.97 )
APPY' s 10-Year Quick Ratio Range
Min: 0.16   Max: 13.97
Current: 13.97

0.16
13.97

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.70
APPY's Price/Net Cash is ranked higher than
100% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. APPY: 0.70 )
APPY' s 10-Year Price/Net Cash Range
Min: 2.6   Max: 17.25
Current: 0.7

2.6
17.25
Price/Net Current Asset Value 0.70
APPY's Price/Net Current Asset Value is ranked higher than
99% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. APPY: 0.70 )
APPY' s 10-Year Price/Net Current Asset Value Range
Min: 2.57   Max: 15.31
Current: 0.7

2.57
15.31
Price/Tangible Book 0.70
APPY's Price/Tangible Book is ranked higher than
99% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.80 vs. APPY: 0.70 )
APPY' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 97.5
Current: 0.7

1.52
97.5
Earnings Yield (Greenblatt) 125.80
APPY's Earnings Yield (Greenblatt) is ranked higher than
100% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. APPY: 125.80 )
APPY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 116.2   Max: 989.2
Current: 125.8

116.2
989.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AP4B.Germany,
Venaxis Inc was organized on July 24, 2000, as a Colorado corporation. In December 2012, the Company's name was changed to Venaxis, Inc., from AspenBio Pharma, Inc. The Company is engaged in development and commercialization of products that address unmet diagnostic and therapeutic needs. The Company's product candidate, APPY1, is designed to be a novel blood-based diagnostic test that, if successfully cleared to be marketed by the United States Food and Drug Administration (FDA), will aid, through the test's negative predictive value, in the evaluation of low risk patients initially suspected of having acute appendicitis, thereby helping address the difficult challenge of triaging possible acute appendicitis patients in the hospital emergency department or urgent care settings. The APPY1, is intended to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2 - 20) that present with abdominal pain. The FDA has regulatory marketing authority in the United States over its APPY1 products. The Company operates under ISO9001-4385 standards for cGMP manufacturing of medical devices. The Company is subject to various environmental laws pertaining to the disposal of hazardous medical waste. It contracts for disposal of hazardous waste with a licensed disposal facility.
» More Articles for NAS:APPY

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 05 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Aug 01 2010 
advise??? Apr 28 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2009 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 07 2009 
AspenBio Pharma Inc. (APPY) CEO Daryl Faulkner buys 10,000 Shares May 21 2009 
AspenBio Pharma Inc. (APPY) COO & Chief Medical Officer Robert Frederick Caspari buys 3,200 Shares May 19 2009 

More From Other Websites
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 07 2015
Venaxis to Provide Business Update Apr 06 2015
VENAXIS, INC. Financials Apr 03 2015
3 Stocks Under $10 Triggering Breakout Trades Apr 02 2015
VENAXIS, INC. Files SEC form 10-K, Annual Report Mar 30 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving... Mar 24 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in... Mar 20 2015
APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Venaxis,... Mar 20 2015
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action... Mar 19 2015
VENAXIS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Mar 18 2015
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Mar 13 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving... Mar 10 2015
VENAXIS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess... Mar 09 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in... Mar 06 2015
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against... Mar 04 2015
APPY SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Venaxis,... Mar 03 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Feb 24 2015
APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Venaxis,... Feb 24 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Feb 20 2015
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced by Law Offices of Howard G.... Feb 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK